Please assess the completion status of the following clinical trial:

Trial Title: Desogestrel-containing COCP Pharmacokinetic Validation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy females aged 18-45 years~* Body-mass index ≥18.5kg/m2~* Willing to abstain from medications and supplements known to induce/inhibit CYP3A4 during the study~* Normal blood pressure measurement at screening (systolic \<140mmHg, diastolic \<90mmHg)~* Negative urine pregnancy test at screening~Exclusion Criteria:~* Currently taking any known CYP3A4 inducers/inhibitors~* Medical conditions that affect liver function (e.g. hepatitis, cirrhosis)~* Any contraindications to estrogen-containing contraception (based on any category 3 or 4 recommendations from the CDC MEC guidelines)~* Use of an injectable contraceptive method within the last 6 months or current use of an ENG contraceptive implant~* Childbirth within the last 6 months~* Known allergy or insensitivity to combined oral contraceptive pills

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Overall Cohort (Type: EXPERIMENTAL): Combined oral contraceptive pill containing 0.15mg desogestrel and 0.03mg ethinyl estradiol for 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).